At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 117 enrolled
Drug / intervention
CH505TF +5 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adult Participants
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Jul 18, 2017·Updated May 4, 2026
In Brief
A Phase 1 clinical trial evaluating CH505TF, CH505w53, and 4 other interventions for HIV Infections. Completed, enrolled 117 participants across 8 sites.
Detailed Summary
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs adjuvanted with GLA-SE in healthy, HIV-uninfected adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedJul 2017
Enrollment StartAug 2017
Primary CompletionMar 2023
TodayJul 2026
First PostedJul 18, 2017
Enrollment StartAug 22, 2017
Primary CompletionMar 21, 2023
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 9.0 years ago
Interventions
CH505TFbiological
Administered by intramuscular (IM) injection in the thigh
CH505w53biological
Administered by IM injection in the thigh
CH505w78biological
Administered by IM injection in the thigh
CH505 M5biological
Administered by IM injection in the thigh
GLA-SE adjuvantbiological
Admixed with all CH505 gp120 proteins
Placebobiological
Administered by IM injection in the thigh